Xaboplax 10 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

xaboplax 10 mg filmom obložene tablete

sandoz d.o.o., maksimirska 120, zagreb, hrvatska - rivaroksaban - filmom obložena tableta - urbroj: svaka filmom obložena tableta sadrži 10 mg rivaroksabana

Xaboplax 2,5 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

xaboplax 2,5 mg filmom obložene tablete

sandoz d.o.o., maksimirska 120, zagreb, hrvatska - rivaroksaban - filmom obložena tableta - urbroj: svaka filmom obložena tableta sadrži 2,5 mg rivaroksabana

Xarelto Europska Unija - hrvatski - EMA (European Medicines Agency)

xarelto

bayer ag - rivaroksaban - arthroplasty, replacement; venous thromboembolism - antitrombotska sredstva - xarelto, uvedene zajedno sa ацетилсалициловой kiselinom (ask) sami ili sa asc plus клопидогрел ili Тиклопидин, prikazana za prevenciju атеротромботических događaja kod odraslih pacijenata nakon akutnog koronarni sindrom (acs) s povišenom razinom кардиальных biomarkera. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. prevencija venske tromboembolije (vte) u odraslih bolesnika koji se podvrgavaju izborni operacije zamjena kuka ili koljena. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.